我们的网站为什么显示成这样?

可能因为您的浏览器不支持样式,您可以更新您的浏览器到最新版本,以获取对此功能的支持,访问下面的网站,获取关于浏览器的信息:

|本期目录/Table of Contents|

红花黄色素注射液辅助治疗冠心病心绞痛疗效的Meta分析*(PDF)

《云南中医学院学报》[ISSN:1000-2723/CN:53-1048/R]

期数:
2021年05期
页码:
25-33
栏目:
临床研究
出版日期:
2022-09-20

文章信息/Info

Title:
Meta-analysis of Therapeutic Efficacy of Safflower Yellow Injection Combined with Conventional Therapy in the Treatment of Angina Pectoris of Coronary Heart Disease
文章编号:
1000 - 2723(2021)05- 0025 - 09
作者:
闫月峰1王海芳2何锐3于远望2△
(1. 陕西中医药大学基础医学院,陕西 西安 712046;2. 陕西中医药大学整合医学研究院,陕西省中西医结合心血管病防治重点实验室,陕西 西安 712046;3. 陕西中医药大学第二附属医院心内科,陕西 西安 712000)
Author(s):
YAN Yuefeng1 WANG Haifang2 HE Rui3 YU Yuanwang2
(1. School of Basic Medicine, Shaanxi University of Traditional Chinese Medicine, Xi'an 712046, China;2. Shaanxi University of Traditional Chinese Medicine Institute of Integrated Medicine, Shaanxi Key Laboratory of Integrated Traditional Chinese and WesternMedicine, Xi'an 712046, China; 3. Department of Cardiology, the Second Affiliated Hospital of Shaanxi University of Traditional Chinese Medicine, Xi'an 712000,China)
关键词:
花黄色素注射液冠心病心绞痛临床随机对照试验Meta分析
Keywords:
safflower yellow injection CHD Angina Pectoris clinical randomized controlled trial Meta-analysis
分类号:
R259
DOI:
10.19288/j.cnki.issn.1000-2723.2021.05.005
文献标识码:
A
摘要:
目的 系统评价红花黄色素注射液联合常规治疗对比常规治疗在冠心病心绞痛治疗的有效性,为临床用药提供循证参考。方法 检索PubMed、Medline、Embase、The Cochrane Library、中国知网、万方数据库、维普数据库、读秀数据库中红花黄色素注射液在辅助治疗冠心病心绞痛方面的临床随机对照试验(randomized controlled trials,RCT),检索时限为2009年1月1日-2020年12月31日,通过RevMan5.4进行Meta分析。结果最终纳入19个随机对照试验,共计2 050例冠心病心绞痛患者,其中试验组1 027例患者,对照组1 023例患者。结果 临床总有效率的评估分析共包含10项研究,结果显示试验组临床总有效率优于对照组[OR=3.32,95%CI(2.18,5.06),Z=5.57,P<0.000 01]。心电图的评估分析共包含9项研究,结果显示试验组优于对照组[OR=1.33,95%CI(1.15,1.54),Z=3.89,P<0.000 01]。心绞痛改善的评估分析共包含7项研究,结果显示试验组优于对照组[OR=4.98,95%CII(3.45,7.19),Z=8.59,P<0.000 01]。高切全血黏度的评估分析共包含4项研究,结果表明试验组优于对照组[MD=-0.35,95%CI(-0.52,-0.19),Z=4.24,P<0.000 1]。低切全血黏度的评估分析共包含4项研究,结果表明试验组优于对照组[MD=-1.18,95%CI(-2.22,-0.14),Z=2.22,P<0.000 01]。血浆黏度的改善的评估分析共包含4项研究,结果表明试验组优于对照组[MD=-0.14,95%CI(-0.18,-0.09),Z=5.54,P<0.000 01]。血细胞比容改善的评估分析共包含2项研究,结果表明试验组优于对照组[MD=-2.15,95%CI(-5.70,1.40),Z=1.19]。纤维蛋白原改善的评估分析共包含2项研究,结果表明试验组优于对照组[MD=-0.27,95%CI(-0.92,0.37),Z=0.83,P<0.000 01]。血清BNP改善的评估分析共包含2项研究,结果表明试验组优于对照组[MD=-38.86,95%CI(-61.37,-16.35),Z=3.38],血清CRP改善的评估分析共包含2项研究,结果表明试验组优于对照组[MD=-2.37,95%CI(-5.56,0.81),Z=1.46]。结论 采用红花黄色素注射液联合西医常规治疗冠心病心绞痛有明显临床总疗效,在改善患者心绞痛症状、改善患者心电图、改善患者血流变学、降低患者血清BNP、CRP等指标方面效果显著,优于西医常规治疗。
Abstract:
Objective To systematically evaluate the efficacy of safflower yellow injection combined with conventional treatment to compare with the conventional therapy in the treatment of Coronary Heart Disease Angina Pectoris, so as to provide evidence-based reference for clinical medication application. Methods Randomized controlled trials(RCTs) about safflower yellow injection preparation treating Angina Pectoris of Coronary Heart Disease from PubMed, Medline, Embase, The Cochrane Library, CNKI, Wanfang Database, CQVIP, and Duxiu Datebase were retrieved and these references were collected from January 1, 2009 to December 31, 2020. Meta analyses were performed with RevMan 5.4 Software. A total of 19RCTs(2050 cases were covered, including 1027 cases in experimental group and 1023 in control group). Results The total clinical effective rate assessment analysis was conducted in 10 studies and the findings showed the total clinical effective rate of the experimental group was better than the control group [OR=3.32, 95%CI(2.18, 5.06), Z=5.57, P<0.000 01]. The evaluation analysis of the ECG consisted of nine studies and the results showed that the experimental group was superior to the control group [OR=1.33, 95%CI(1.15, 1.54), Z=3.89, P<0.000 01]. The assessment analysis of angina improvement included seven studies, and the results showed that the experimental group was superior to the control group [OR=4.98, 95%CI(3.45, 7.19), Z=8.59, P<0.000 01]. The evaluation analysis of whole blood high shear viscosity included four studies, and the results showed that the experimental group was superior to the control group [MD=-0.35, 95%CI(-0.52, -0.19), Z=4.24, P<0.000 1]. The evaluation analysis of whole blood low shear viscosity included four studies, and the results showed the experimental group surpassed the control group[MD=-1.18, 95%CI(-2.22, -0.14), Z=2.22, P<0.000 01]. The evaluation analysis of improvement in plasma viscosity consisted of studies, and the results showed that the experimental group was better than the control group[MD=-0.14, 95%CI(-0.18, -0.09), Z=5.54, P<0.000 01]. The assessed analysis of the improvement in hematocrit included two studies, and the results showed that the experimental group was superior to the control group[MD=-2.15, 95%CI(-5.70, 1.40), Z=1.19]. The evaluation analysis of fibrinogen improvement included two studies, the results that the experimental group surpassed the control group[MD=-0.27, 95%CI(-0.92, 0.37), Z=0.83, P<0.000 01]. The assessment analysis of serum BNP improvement included 2 studies, and the results showed that the experimental group was superior to the control group [MD=-38.86, 95%CI(-61.37, -16.35), Z=3.38]. The evaluation analysis of serum CRP improvement included 2 studies, the findings showed that the experimental group was superior to the control group[MD=-2.37, 95%CI(-5.56, 0.81), Z=1.46]. Conclusion The routine treatment of safflower yellow injection combined with western medicine has obvious total clinical effect rate in improving patients' ECG, blood rheology, reducing serum BNP, CRP and other indicators, which is better than the conventional treatment of western medicine.

参考文献/References

[1] CYBULSKA B,K?覵OSIEWICZ-LATOSZEK L. Landmark studies in coronary heart disease epidemiology. The Framingham Heart Study after 70 years and the Seven Countries Study after 60 years[J]. Kardiol Pol,2019,77(2):173-180.
[2] LIU Y J,LI Z,SHEN D D,et al. Adjuvant treatment of coronary heart disease angina pectoris with Chinese patent medicine:a prospective clinical cohort study[J]. Medicine(Baltimore),2019,98(33):e16884.
[3] 李亥辰,陈柏君,熊磊,等. 芳香温通方药防治冠心病心绞痛的研究进展[J]. 中华中医药学刊,2021,39(1):202-205.
[4] 李正阳,卞希岚,周文垚,等. 中医治疗冠心病心绞痛概况[J]. 湖南中医杂志,2018,34(11):155-157.
[5] 陈可冀,付长庚,丛伟红,等. 红花黄色素临床应用中国专家共识[J]. 中国中西医结合杂志,2017,37(10):1167-1173.
[6] WANG H F,LIU J L,YANG Y J,et al. Hydroxy-safflower yellow A inhibits the TNFR1-mediated classical NF-κB pathway by inducing shedding of TNFR1[J]. Phytother Res, 2016,30(5):790-796.
[7] 张国强,张杰,夏阳,等. 红花黄色素的研究进展[J]. 世界临床药物,2015,36(7):491-494.
[8] 史敏,陈雷,龚佳佳,等. 红花黄色素的研究进展[J]. 世界最新医学信息文摘,2018,18(8):20.
[9] 宋轶群. 红花黄色素注射液治疗冠心病心绞痛心血瘀阻证疗效观察[J]. 中国中医急症,2009,18(11):1755.
[10] 马艳娜. 注射用红花黄色素联合琥珀酸美托洛尔缓释片对冠心病心绞痛的疗效观察[J]. 河南医学研究,2018,27(16):2990-2991.
[11] 徐国良,秦玲. 红花黄色素氯化钠注射液治疗冠心病心绞痛临床观察[J]. 中国中医急症,2011,20(12):2002.
[12] 李晓军,韩毅,高建辉. 红花黄色素治疗心血瘀阻型冠心病心绞痛随机平行对照研究[J]. 实用中医内科杂志,2013,27(18):23-25.
[13] 王娟,邓丽娜,刘璠,等. 红花黄色素治疗心血瘀阻证冠心病心绞痛患者的临床效果[J]. 陕西中医,2016,37(1):31-32.
[14] 王彦普,迟光玉. 红花黄色素注射液治疗冠心病心绞痛疗效观察[J]. 医药前沿,2013,(13):231-232.
[15] 李世欣,王秋爽. 注射用红花黄色素治疗冠心病心绞痛的临床观察[J]. 中国社区医师(医学专业),2010,12(32):110.
[16] 李卫东. 单硝酸异山梨酯联合红花黄色素治疗冠心病心绞痛258例疗效观察[J]. 临床医药实践,2015,24(1):70-72.
[17] 崔秀春,尹维斌,廖中廷,等. 红花黄色素氯化钠注射液联合普萘洛尔治疗冠心病心绞痛的临床研究[J]. 现代药物与临床,2019,34(8):2287-2292.
[18] 刘华. 在常规西药基础上结合红花黄色素治疗冠心病心绞痛的临床价值[J]. 内蒙古中医药,2017,36(4):77.
[19] 靳秀芹. 红花黄色素与异山梨酯治疗冠心病心绞痛[J]. 中国继续医学教育,2020,12(18):159-161.
[20] 陈泽海. 红花黄色素联合硝酸甘油治疗冠心病心绞痛的临床效果及对患者BNP、CRP水平的影响[J]. 医学理论与实践,2020,33(12):1933-1935.
[21] 孙慎波. 红花黄色素治疗冠心病心绞痛36例临床观察[J]. 世界最新医学信息文摘,2015,15(49):102.
[22] 唐立明,白云,陈梅芳,等. 注射用红花黄色素治疗冠心病心绞痛100例临床观察[J]. 中医临床研究,2017,9(1):69-71.
[23] 巴特尔. 红花黄色素联合单硝酸异山梨酯治疗冠心病心绞痛72例临床观察[J]. 中国民族民间医药,2014,23(18):66.
[24] 房楷源,康建琴,丁志松,等. 红花黄色素注射液辅助治疗冠心病心绞痛的效果及对患者血液流变学的影响[J]. 慢性病学杂志,2019,20(7):1060-1061.
[25] 徐智. 注射用红花黄色素治疗心血瘀阻证冠心病心绞痛患者的临床观察[J]. 黑龙江医药,2018,31(1):34-36.
[26] 韩标定. 红花黄色素氯化钠注射液治疗冠心病心绞痛疗效观察[J]. 中国现代药物应用,2013,7(18):98-99.
[27] 李翔. 红花黄色素治疗冠心病心绞痛78例疗效观察[J]. 医学信息,2013(11):178-179.
[28] 中国心血管健康与疾病报告编写组. 中国心血管健康与疾病报告2020概要[J]. 中国循环杂志,2021,36(6):521-545.
[29] WAHEED N,MAHMOUD A,RAMBARAT C A,et al. Advances in small-molecule therapy for managing angina pectoris in the elderly[J]. Expert Opin Pharmacother,2019,20(12):1471-1481.
[30] CHEN M C,WANG M M,YANG Q,et al. Antioxidant effects of hydroxysafflor yellow A and acetyl-11-keto-β-boswellic acid in combination on isoproterenol-induced myocardial injury in rats[J]. Int J Mol Med,2016, 37(6):1501 - 1510.
[31] ZHUANG J Q,DAI X Z,ZHANG H B,et al. A meta-analysis for Kuanxiong Aerosol on the treatment of angina pectoris[J]. Am J Emerg Med,2020,38(6):1218-1225.
[32] 贾文侠,祁丽蓉. NT-proBNP和凝血功能相关指标对冠心病患者预后的预测价值[J]. 中国卫生工程学,2020,19(3):397-399.
[33] 国家卫生计生委合理用药专家委员会,中国药师协会. 冠心病合理用药指南(第2版)[J]. 中国医学前沿杂志(电子版),2018,10(6):1-130.

备注/Memo

备注/Memo:
收稿日期: 2021 - 08- 29
* 基金项目: 陕西省中医药管理局资助类研究课题(2019-ZZ-JC025);陕西中医药大学第二附属医院学科创新团队项目(2020XKTD-B02)
第一作者简介: 闫月峰(1982-),男,在读硕士研究生,研究方向:心血管病中西医结合防治。
△通信作者: 于远望,E-mail: yuyw2003214@163.com
更新日期/Last Update: 1900-01-01